Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
23.60
-4.06 (-14.67%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.

The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson’s disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities.

It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin’s lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors.

The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.

Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Ltd.
Biohaven logo
Country United States
Founded 2013
IPO Date May 4, 2017
Industry Biotechnology
Sector Healthcare
Employees 256
CEO Vladimir Coric

Contact Details

Address:
215 Church Street
New Haven, Connecticut 06510
United States
Phone 203 404 0410
Website biohaven.com

Stock Details

Ticker Symbol BHVN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001935979
CUSIP Number G11196105
ISIN Number VGG1110E1079
SIC Code 2834

Key Executives

Name Position
Dr. Vladimir Coric M.D. Chairman and Chief Executive Officer
Matthew Buten Chief Financial Officer
Dr. Bruce D. Car DACVP, Ph.D. Chief Scientific Officer
Kimberly Gentile Senior Vice President of Clinical Operations
Deb Young Senior Director of Regulatory Affairs and Operations
Jennifer Porcelli Vice President of Investor Relations
Warren Volles J.D. General Counsel and Chief Legal Officer
Clifford Bechtold M.S. President, GM of Biohaven Ireland and Chief Compliance Officer
John Tilton Chief Commercial Officer of Rare Diseases
Chris Barrett Senior Vice President of Commercial Strategy, Common Disease

Latest SEC Filings

Date Type Title
Mar 18, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 18, 2025 DEF 14A Other definitive proxy statements
Mar 3, 2025 8-K Current Report
Mar 3, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals